Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2022-07-08 4:57 pm Sale | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 3,755,757 2.2% | -6,252,753 (-62.47%) | View |
| 2022-03-25 5:23 pm Purchase | 13D | Lineage Cell Therapeutics, Inc. LCTX | BROADWOOD PARTNERS L.P. | 35,227,273 20.7% | 980,106 (+2.86%) | View |
| 2022-02-04 4:12 pm Purchase | 13G | Lineage Cell Therapeutics, Inc. LCTX | BlackRock Inc. BLK | 10,008,510 5.9% | 10,008,510 (New Position) | View |
| 2021-03-16 5:04 pm Purchase | 13D | Lineage Cell Therapeutics, Inc. LCTX | BROADWOOD PARTNERS L.P. | 34,247,167 21.2% | 335,268 (+0.99%) | View |
| 2021-01-08 5:00 pm Sale | 13D | OncoCyte Corporation OCX | Lineage Cell Therapeutics Inc. LCTX | 3,297,401 4.9% | -968,503 (-22.70%) | View |
| 2020-04-27 5:28 pm Sale | 13D | OncoCyte Corporation OCX | Lineage Cell Therapeutics Inc. LCTX | 4,265,904 6.3% | -1,775,250 (-29.39%) | View |
| 2020-02-14 4:45 pm Purchase | 13D | Lineage Cell Therapeutics Inc. BTX | GREENBELT CORP | 5,697,875 3.62% | 5,697,875 (New Position) | View |
| 2020-01-06 5:00 pm Sale | 13D | OncoCyte Corporation OCX | Lineage Cell Therapeutics Inc. LCTX | 6,041,154 10% | -2,383,090 (-28.29%) | View |
| 2019-09-13 5:18 pm Sale | 13D | OncoCyte Corporation OCX | Lineage Cell Therapeutics Inc. LCTX | 8,424,244 16.2% | -4,000,000 (-32.20%) | View |
| 2019-07-05 4:30 pm Sale | 13D | OncoCyte Corporation OCX | Lineage Cell Therapeutics Inc. LCTX | 12,424,244 23.9% | -2,250,000 (-15.33%) | View |
| 2019-03-12 5:02 pm Purchase | 13D | Lineage Cell Therapeutics Inc. BTX | BROADWOOD PARTNERS L.P. | 33,911,899 22.4% | 6,579,737 (+24.07%) | View |
| 2019-03-11 7:07 pm Sale | 13D | Asterias Biotherapeutics Inc. AST | Lineage Cell Therapeutics Inc. LCTX | 0 0% | -21,747,569 (Position Closed) | View |
| 2018-11-08 5:13 pm Unchanged | 13D | Asterias Biotherapeutics Inc. AST | Lineage Cell Therapeutics Inc. LCTX | 21,747,569 39.2% | 0 (Unchanged) | View |
| 2018-08-21 9:47 pm Unchanged | 13D | OncoCyte Corporation OCX | Lineage Cell Therapeutics Inc. LCTX | 14,674,244 36.1% | 0 (Unchanged) | View |
| 2018-05-18 4:10 pm Unchanged | 13D | OncoCyte Corporation OCX | Lineage Cell Therapeutics Inc. LCTX | 14,674,244 37.2% | 0 (Unchanged) | View |
| 2018-04-03 4:24 pm Unchanged | 13D | OncoCyte Corporation OCX | Lineage Cell Therapeutics Inc. LCTX | 14,674,244 38.8% | 0 (Unchanged) | View |